{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-252642","form_type":"8-K","ticker":"PHAT","cik":"0001783183","company_name":"Phathom Pharmaceuticals, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.605018+00:00","generated_at":"2026-05-30T03:43:00.969464+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Phathom Q3 net revenues $16.4M, up >120% QoQ; net loss $85.6M; VOQUEZNA prescriptions exceed 143k launch-to-date","bullets":["Net revenues $16.4M for Q3 2024 (vs $7.3M Q2 2024); no revenues in Q3 2023.","Over 143,000 prescriptions for VOQUEZNA products filled launch-to-date (138% increase since last quarterly report).","Net loss $85.6M vs $43.2M in Q3 2023; non-GAAP adjusted net loss $67.9M vs $30.8M.","Commercial access expanded to >80% of U.S. commercial lives (est. 120M covered lives).","R&D expenses down to $8.7M; SG&A up to $76.1M due to commercial buildout."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-252642","json":"https://secwatch.observer/filing/0001193125-24-252642.json","markdown":"https://secwatch.observer/filing/0001193125-24-252642.md","text":"https://secwatch.observer/filing/0001193125-24-252642.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783183/000119312524252642/0001193125-24-252642-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783183/000119312524252642/d885289d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:43:00.969464+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}